Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBE2Q1 antisense RNA 1 (UBE2Q1-AS1) is a long non-coding RNA transcribed in the antisense orientation relative to the UBE2Q1 gene. As a member of the antisense RNA class, it is presumed to act primarily as a regulator of gene expression, potentially affecting the expression, processing, or stability of the UBE2Q1 sense transcript or other related genes. Antisense RNAs such as UBE2Q1-AS1 can modulate transcription and epigenetic states, participate in chromatin remodeling, or influence mRNA splicing and stability, with dysregulation linked to diseases including various cancers[2][3]. UBE2Q1-AS1 itself is not a protein-coding gene nor considered a canonical therapeutic target such as a receptor or enzyme, though interest in non-coding RNAs as drug targets is increasing due to their implications in gene regulation and disease[2][3].
Not applicable (UBE2Q1-AS1 is not a direct target for current drugs, but antisense RNA may be modulated by antisense oligonucleotide therapeutics in general[2])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UBE2Q1 antisense RNA 1 (UBE2Q1-AS1).